Given that the angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARB) could augment ACE2 expression, we analyzed whether ACEI/ARB treatment would have an impact on the incidence and recovery time of COVID-19 in patients with chronic liver disease complicated by hypertension (n = 127). The gene discussed is ACE2; the disease is COVID-19.